A uniquely tailored education program to help you with the challenges you face as a CML clinician in an emerging region.

**SELECTION CRITERIA**

The iCMLf seeks to improve the resources and knowledge of physicians treating patients with CML in emerging economic regions.

The iCMLf will select hematologists for the program whose attendance is expected to provide most benefit in this CML community.

Candidates should have a special interest in CML management and be able to demonstrate their ability to apply and disseminate the knowledge gained from the program to their colleagues.

**APPLICATION PROCESS**

To apply for the program, please complete the application form found at www.cml-foundation.org or by emailing arlene@cml-foundation.org.

Applications close on 15 December

Applications received after this date will be reviewed if additional preceptorship places become available.

Once selected, applicants will be matched with the most appropriate host site according to location, timing, language spoken and other individual needs.

Specific requirements such as visas, insurance and work permits will be determined during the individual application process.

If you have any queries about the iCMLf Clinical Preceptorship Program, please contact Arlene Harriss-Buchan, Program Coordinator arlene@cml-foundation.org
“The knowledge and skills after the exposure to an advanced center has helped me in taking bold and confident decision making.”

Dr Gul, Pakistan
A UNIQUELY TAILORED EDUCATION PROGRAM TO HELP YOU WITH THE CHALLENGES YOU FACE AS A CML CLINICIAN IN AN EMERGING REGION

CLINICAL PRECEPTORSHIP PROGRAM CONTENT

This unique opportunity would see you undertake a 3-4 week intensive education program at a global CML centre of excellence under the leadership of some of the world’s most experienced hematologists. As a part of the clinical team at your host site you may participate in:

- Out-patient clinics
- Hematology ward rounds
- Seminars
- Discussion forums
- Laboratory work

The program would be tailored to your needs, with consideration to your level of experience, along with the challenges and the resources available to you at your institution.

This can include:

- therapies to treat CML; efficacy, toxicity and the management of side effects
- monitoring guidelines
- management of resistance
- role of allograft in CML
- developments in novel therapies, vaccines and drug cessation

The preceptorships are designed as an interactive process with participants steering their own education throughout the program. Upon your return home, and armed with a solid understanding of the most up to date protocols and guidelines to treat CML, you would have considerable information to share with your colleagues. Through the establishment of networks and contacts, the benefits can continue well into the future.
<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>Preceptorship Program Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Algeria</td>
<td>![Image]</td>
</tr>
<tr>
<td>Argentina</td>
<td>![Image]</td>
</tr>
<tr>
<td>Armenia</td>
<td>![Image]</td>
</tr>
<tr>
<td>Azerbaijan</td>
<td>![Image]</td>
</tr>
<tr>
<td>Bangladesh</td>
<td>![Image]</td>
</tr>
<tr>
<td>Belarus</td>
<td>![Image]</td>
</tr>
<tr>
<td>Bolivia</td>
<td>![Image]</td>
</tr>
<tr>
<td>Brazil</td>
<td>![Image]</td>
</tr>
<tr>
<td>Burkina Faso</td>
<td>![Image]</td>
</tr>
<tr>
<td>Chile</td>
<td>![Image]</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>![Image]</td>
</tr>
<tr>
<td>Ecuador</td>
<td>![Image]</td>
</tr>
<tr>
<td>Egypt</td>
<td>![Image]</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>![Image]</td>
</tr>
<tr>
<td>Gabon</td>
<td>![Image]</td>
</tr>
<tr>
<td>Ghana</td>
<td>![Image]</td>
</tr>
<tr>
<td>Guatemala</td>
<td>![Image]</td>
</tr>
<tr>
<td>Guinea</td>
<td>![Image]</td>
</tr>
<tr>
<td>Haiti</td>
<td>![Image]</td>
</tr>
<tr>
<td>Honduras</td>
<td>![Image]</td>
</tr>
<tr>
<td>Iraq</td>
<td>![Image]</td>
</tr>
<tr>
<td>India</td>
<td>![Image]</td>
</tr>
<tr>
<td>Indonesia</td>
<td>![Image]</td>
</tr>
<tr>
<td>Jamaica</td>
<td>![Image]</td>
</tr>
<tr>
<td>Kazakhstan</td>
<td>![Image]</td>
</tr>
<tr>
<td>Kenya</td>
<td>![Image]</td>
</tr>
<tr>
<td>Kyrgyzstan</td>
<td>![Image]</td>
</tr>
<tr>
<td>Macedonia</td>
<td>![Image]</td>
</tr>
<tr>
<td>Madagascar</td>
<td>![Image]</td>
</tr>
<tr>
<td>Malawi</td>
<td>![Image]</td>
</tr>
<tr>
<td>Malaysia</td>
<td>![Image]</td>
</tr>
<tr>
<td>Moldova</td>
<td>![Image]</td>
</tr>
<tr>
<td>Mongolia</td>
<td>![Image]</td>
</tr>
<tr>
<td>Nepal</td>
<td>![Image]</td>
</tr>
<tr>
<td>Niger</td>
<td>![Image]</td>
</tr>
<tr>
<td>Nigeria</td>
<td>![Image]</td>
</tr>
<tr>
<td>Pakistan</td>
<td>![Image]</td>
</tr>
<tr>
<td>Papua New Guinea</td>
<td>![Image]</td>
</tr>
</tbody>
</table>

**PROGRAM REACH TO DATE**

<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>Preceptorship Program Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paraguay</td>
<td>![Image]</td>
</tr>
<tr>
<td>Peru</td>
<td>![Image]</td>
</tr>
<tr>
<td>Philippines</td>
<td>![Image]</td>
</tr>
<tr>
<td>Romania</td>
<td>![Image]</td>
</tr>
<tr>
<td>Russia</td>
<td>![Image]</td>
</tr>
<tr>
<td>Senegal</td>
<td>![Image]</td>
</tr>
<tr>
<td>Sri Lanka</td>
<td>![Image]</td>
</tr>
<tr>
<td>Sudan</td>
<td>![Image]</td>
</tr>
<tr>
<td>Tanzania</td>
<td>![Image]</td>
</tr>
<tr>
<td>Thailand</td>
<td>![Image]</td>
</tr>
<tr>
<td>Tunisia</td>
<td>![Image]</td>
</tr>
<tr>
<td>Uganda</td>
<td>![Image]</td>
</tr>
<tr>
<td>Ukraine</td>
<td>![Image]</td>
</tr>
<tr>
<td>Uruguay</td>
<td>![Image]</td>
</tr>
<tr>
<td>Uzbekistan</td>
<td>![Image]</td>
</tr>
<tr>
<td>Venezuela</td>
<td>![Image]</td>
</tr>
<tr>
<td>Vietnam</td>
<td>![Image]</td>
</tr>
</tbody>
</table>

---

**07**
Professor Franck Nicolini  
Centre Léon Bérard, 28 rue Laennec, 69373 Lyon, France  
LANGUAGE/S: FRENCH

**08**
Professor Jerry Radich  
Fred Hutchinson Cancer Research Center  
Seattle, USA  
LANGUAGE/S: ENGLISH

**09**
Professor Gianantonio Rosti  
S.Orsola-Malpighi University Hospital  
Bologna, Italy  
LANGUAGE/S: ITALIAN & ENGLISH

**10**
Professor David Snyder  
City of Hope  
California, USA  
LANGUAGE/S: ENGLISH

**11**
Professor Juan-Luis Steegmann  
Hospital Universitario de la Princesa  
Madrid, Spain  
LANGUAGE/S: SPANISH

**12**
Professor Andrey Zaritsky  
Almazov Federal Centre of Heart, Blood and Endocrinology  
St Petersburg, Russia  
LANGUAGE/S: RUSSIAN